Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease
Notified -
Globe Newswire17-04-2025, 03:44
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients 9-09-2024, 22:45
